NCI Clinical and Translational Exploratory/Developmental Studies (R21) | Apply Online

FAQs: NCI Clinical and Translational Exploratory/Developmental Studies (R21) - PAR-16-176

What is the NCI Clinical and Translational Exploratory/Developmental Studies (R21) opportunity (PAR-16-176)?

This is a National Cancer Institute (NCI) funding opportunity that uses the NIH R21 mechanism to support early-stage, high-potential clinical and translational cancer research ideas that are not yet ready for larger clinical testing or full development awards.

What is the main purpose of the NIH R21 mechanism in this program?

The R21 mechanism is intended for exploratory and developmental projects where the central goal is to generate key proof-of-concept data, establish feasibility, or develop a novel approach that can quickly open a new direction in cancer research.

Does this program support high-risk, high-reward projects?

Yes. The program is described as being comfortable supporting projects that carry meaningful scientific risk, as long as the potential payoff is substantial, such as enabling a first-in-human study or creating a new method or model that changes how a problem is approached.

What scientific areas are targeted by this funding opportunity?

The FOA targets clinical and translational research tied closely to cancer diagnosis, treatment, imaging, symptom and toxicity research, and cancer prevention.

Are correlative studies connected to clinical trials a major focus?

Yes. A major emphasis is on correlative studies connected to clinical trials, meaning research that accompanies or leverages clinical trial activity to understand mechanisms, biomarkers, response patterns, resistance, toxicity drivers, and other biological or clinical signals that explain why an intervention works (or fails) and for whom.

What kinds of therapeutic development activities are supported?

The announcement supports exploratory research that advances development of novel cancer therapeutics, agents intended to prevent cancer, and interventions focused on symptom management or reducing treatment-related toxicities.

Is radiotherapy development included within the scope?

Yes. The opportunity highlights radiotherapy development activities as an area of interest.

Does the FOA encourage combination strategies (multi-agent or multi-modality)?

Yes. It specifically highlights mechanism-driven combinations and reflects NCI interest in rationally designed multi-agent or multi-modality strategies that are grounded in biology rather than purely empirical pairing.

Are preclinical studies eligible, or is this limited to human clinical work?

Preclinical studies are supported when they are explicitly intended to be clinically relevant. The focus is not basic science for its own sake, but work positioned to inform clinical decision-making or accelerate entry into human testing.

What types of preclinical approaches are emphasized as clinically relevant?

The FOA emphasizes development or use of newer model systems that better reflect human disease biology and treatment response, and the use of advanced imaging technologies that can improve diagnosis, guide treatment, measure response, or illuminate biological processes beyond standard methods.

How important is a path toward first-in-human trials?

Projects that can credibly map a path toward first-in-human clinical trials are described as particularly aligned with the stated goals.

Which federal agency administers this grant?

This is a discretionary federal grant administered by HHS/NIH (agency listing shown as HHS-NIH11) through the National Cancer Institute.

What CFDA numbers are associated with this opportunity?

The opportunity is listed under several CFDA numbers associated with NCI research programs: 93.393, 93.394, 93.395, 93.396, and 93.399.

What is the maximum (ceiling) award amount?

The listed award ceiling is $200,000, indicating budgets are expected to be modest and tightly focused on critical experiments or development steps that enable the next stage of translation.

Does the provided information state how many awards are expected?

No. The provided information does not specify the number of expected awards.

What does the program generally look for given the R21 structure?

Based on the description, competitive projects are expected to make a clear case for innovation, feasibility within a limited scope and timeframe, and strong potential impact.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic organizations across public, private, nonprofit, academic, and governmental sectors, consistent with translational cancer research needs.

Are state and local governments eligible applicants?

Yes. Eligible applicants include state governments, county governments, and city or township governments, as well as special district governments.

Are educational institutions eligible?

Yes. Eligible applicants include independent school districts and both public/state-controlled and private institutions of higher education.

Are tribal entities eligible to apply?

Yes. Federally recognized Native American tribal governments and other Native American tribal organizations are listed as eligible.

Are public housing authorities eligible?

Yes. Public housing authorities/Indian housing authorities are included among eligible applicants.

Are nonprofit organizations eligible (including those without 501(c)(3) status)?

Yes. Nonprofits with or without 501(c)(3) status (other than institutions of higher education) are listed as eligible.

Are for-profit organizations eligible, including small businesses?

Yes. Eligible applicants include for-profit organizations other than small businesses, as well as small businesses.

Is there any additional eligibility language beyond the list?

Yes. The provided description notes that there are additional applicant types as described in the FOA's eligibility clarification text.

When was this opportunity posted, and what closing date is provided?

The opportunity was created and posted on April 8, 2016, and the provided closing date for the listed cycle was March 22, 2018.

What kinds of projects are a strong fit for this program based on the description?

Strong-fit projects include bold, early translational ideas that are not yet mature enough for large clinical programs but have a plausible route to near-term clinical relevance. Examples described include enabling first-in-human trials, establishing a new correlative science strategy around an ongoing clinical trial, or delivering enabling tools such as clinically realistic models, advanced imaging approaches, or mechanistically grounded combination strategies.